Dual targeting of egfr/her2 pathway in combination with systemic chemotherapy in refractory conko-008 marianne thomas johann sebastian helmut hanno riess

HIGHLIGHTS

• who: Cancer-The CONKO- and collaborators from the Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany have published the research work: Dual Targeting of EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory CONKO-008 Marianne Thomas Johann Sebastian Helmut Hanno Riess, in the Journal: (JOURNAL)
• what: The aim of the trial was the definition of the maximum tolerable dose of lapatinib in combination with OFF; secondary objectives were safety and efficacy. The trial showed that . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.